{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:05:53Z","timestamp":1782965153013,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:49:02Z","timestamp":1762645742000},"page":"375-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tailoring Intensity: A Perspective on Thiotepa, Busulfan, and Fludarabine (TBF) Conditioning for Acute Leukemias and Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-1177","authenticated-orcid":false,"given":"Zaid","family":"Abdel Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-0694","authenticated-orcid":false,"given":"Mohammad","family":"Ma'koseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5633-687X","authenticated-orcid":false,"given":"Zaid","family":"Muhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: the state of the art","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtct.2025.11.015_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100892","article-title":"Historical perspective and a glance into the antibody-based conditioning regimens: a new era in the horizon?","volume":"52","author":"El Fakih","year":"2022","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.46989\/001c.120991","article-title":"Total body irradiation-based conditioning versus chemotherapy before allogeneic stem cell transplantation for adults with acute lymphoblastic leukemia","volume":"6","author":"Ben Abdeljelil","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.015_bib0004","article-title":"Adverse effects of total body irradiation: a two-decade, single institution analysis","volume":"6","author":"Pearlman","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2025.11.015_bib0005","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0006","first-page":"S108","article-title":"Observational comparison of overall survival between phase 1b orca-T and registry-based post-transplant cyclophosphamide patients","volume":"31","author":"Meyer","year":"2025","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.jtct.2025.11.015_bib0007","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood-2024-204256","article-title":"Preliminary safety and efficacy of myeloablative orca-Q with no GvHD prophylaxis for treatment of advanced hematologic malignancies","volume":"144","author":"Abedi","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0008","first-page":"S107","article-title":"Preliminary safety and efficacy of myeloablative orca-Q with no GvHD prophylaxis for treatment of advanced hematologic malignancies","volume":"31","author":"Salhotra","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0009","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.18632\/oncotarget.23273","article-title":"Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission","volume":"9","author":"Saraceni","year":"2018","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.jtct.2025.11.015_bib0010","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/bloodadvances.2021004779","article-title":"A phase 1\/2 study of thiotepa-based immunochemotherapy in relapsed\/refractory primary CNS lymphoma: the TIER trial","volume":"5","author":"Fox","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.015_bib0011","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.bbmt.2017.06.027","article-title":"Adult umbilical cord blood transplantation using myeloablative thiotepa, total body irradiation, and fludarabine conditioning","volume":"23","author":"Anand","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0012","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-018-0655-8","article-title":"Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine","volume":"11","author":"Giannotti","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0013","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-018-0655-8","article-title":"Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine","volume":"11","author":"Giannotti","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41409-022-01841-0","article-title":"Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation","volume":"58","author":"Banet","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.015_bib0015","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41409-021-01222-z","article-title":"Thiotepa\u2013busulfan\u2013fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT","volume":"56","author":"Battipaglia","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2025.11.015_bib0016","article-title":"Busulfan fludarabine (BU-FLU) compared to thiotepa busulfan fludarabine (TBF) for allogeneic transplants in acute myeloid leukemia (AML) or refractory anemia with excess blasts (RAEB) in remission","volume":"130","author":"Sora","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2011.07.006","article-title":"Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma","volume":"18","author":"Cote","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.015_bib0018","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.015_bib0019","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.015_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3349\/ymj.2020.61.6.452","article-title":"Reduced-intensity conditioning with busulfan and fludarabine for allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia","volume":"61","author":"Lee","year":"2020","journal-title":"Yonsei Med J."},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-019-0727-4","volume":"12","author":"Saraceni","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.11.015_bib0022","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"Myers","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.015_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","article-title":"Association between the magnitude of intravenous busulfan exposure and development of hepatic Veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"28","author":"Bogn\u00e0r","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.015_bib0024","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","article-title":"Optimal prevention of seizures induced by high-dose busulfan","volume":"28","author":"Eberly","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtct.2025.11.015_bib0025","doi-asserted-by":"crossref","unstructured":"Balaguer-Rosell\u00f3 A, Montoro J, Villalba M, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther. doi:10.1016\/j.jtct.2025.05.018","DOI":"10.1016\/j.jtct.2025.05.018"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.1991.9.1.175","article-title":"Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies","volume":"9","author":"Chun","year":"1991","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"Keating","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0028","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1111\/j.1399-3046.2011.01539.x","article-title":"Successful cord blood transplantation with reduced-intensity conditioning for childhood cerebral X-linked adrenoleukodystrophy at advanced and early stages","volume":"16","author":"Niizuma","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2025.11.015_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1287444","article-title":"Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells","volume":"13","author":"Valdez","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0030","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-6-15","volume":"6","author":"Liu","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0032","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-022-01865-6","article-title":"Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis","volume":"58","author":"Luo","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2025.11.015_bib0033","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood.2024025705","article-title":"How I treat AML relapse after allogeneic HSCT","volume":"145","author":"Gooptu","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.11.015_bib0034","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.25225","article-title":"Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia","volume":"93","author":"Saraceni","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.015_bib0035","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0036","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jtct.2025.01.280","article-title":"Allogeneic stem cell transplant with myeloablative fractionated busulfan, fludarabine and thiotepa conditioning regimen in older patients with high risk MDS","volume":"31","author":"Hosing","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.11.015_bib0037","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","article-title":"Thiotepa, fludarabine, and busulfan conditioning regimen before T cell-replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients","volume":"25","author":"Pagliardini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.015_bib0038","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/bloodadvances.2023011759","article-title":"Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up","volume":"8","author":"Raiola","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0039","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41409-020-01074-z","article-title":"Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine\/busulfan conditioning for acute myeloid leukemia","volume":"56","author":"Bazarbachi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.jtct.2025.11.015_bib0040","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Kr\u00f6ger","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0041","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/10428194.2020.1827246","article-title":"Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience","volume":"62","author":"Memoli","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.015_bib0042","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2018.12.064","article-title":"Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO Group","volume":"25","author":"Patriarca","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0043","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41409-019-0653-7","article-title":"Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis","volume":"55","author":"Shouval","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.015_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.802648","article-title":"Role of radiation based conditioning regimens in patients with high-risk AML undergoing allogenic transplantation in remission or active disease and mechanisms of post-transplant relapse","volume":"12","author":"Salhotra","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0045","article-title":"Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission","volume":"15","author":"Lv","year":"2025","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.015_bib0046","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41409-024-02298-z","article-title":"Total body irradiation versus thiotepa\/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia","volume":"59","author":"Mora","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.015_bib0047","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.clml.2024.12.007","article-title":"Efficacy and safety of total body irradiation versus chemotherapy conditioning for hematopoietic stem cell transplant in adult acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Ans","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0048","doi-asserted-by":"crossref","first-page":"171.e1","DOI":"10.1016\/j.jtct.2020.10.008","article-title":"Improved outcomes of haploidentical hematopoietic cell transplantation with total body irradiation-based myeloablative conditioning in acute lymphoblastic leukemia","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0049","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41409-021-01550-0","volume":"57","author":"Swoboda","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.015_bib0050","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","article-title":"Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation","volume":"25","author":"Dul\u00e9ry","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0051","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbmt.2009.11.008","volume":"16","author":"Barba","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.11.015_bib0052","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2020.01.007","article-title":"Effect of the thiotepa dose in the TBF conditioning regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia in complete remission: a report from the EBMT Acute Leukemia Working Party","volume":"20","author":"El-Cheikh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.jtct.2025.11.015_bib0053","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.24823","volume":"92","author":"Eder","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.015_bib0054","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbmt.2016.09.024","article-title":"A comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning","volume":"23","author":"Scordo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.015_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jdcr.2024.09.015","article-title":"Thiotepa-induced toxic erythema of chemotherapy: a case report and review of the histological features","volume":"54","author":"Ofori-Darko","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.015_bib0056","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3109\/10428194.2015.1071488","article-title":"Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide","volume":"57","author":"Lombardi","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.015_bib0057","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41409-023-02150-w","volume":"59","author":"Duque-Afonso","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.015_bib0058","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","article-title":"Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (BUFLU) or thiotepa, busulfan, and fludarabine (TBF): a retrospective study","volume":"26","author":"Sora","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:34:10Z","timestamp":1778355250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666636725015659"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring Intensity: A Perspective on Thiotepa, Busulfan, and Fludarabine (TBF) Conditioning for Acute Leukemias and Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}